Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19071148 | Viral Vectors For Treating Neurogenic Detrusor Overactivity | March 2025 | October 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18616511 | Gene Therapy For Neurodegenerative Disorders | March 2024 | March 2025 | Allow | 11 | 1 | 0 | No | No |
| 18404087 | VECTOR-MEDIATED IMMUNE TOLERANCE IN THE EYE | January 2024 | June 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18534884 | Viral Vectors For Treating Neurogenic Detrusor Overactivity | December 2023 | October 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18488346 | Gene Therapy For Neurodegenerative Disorders | October 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18464908 | METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATION | September 2023 | November 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18224131 | CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPY | July 2023 | October 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18351930 | COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE | July 2023 | March 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18330020 | Protection of Beta Cells from Immune Attack | June 2023 | October 2025 | Allow | 28 | 2 | 0 | No | No |
| 18142133 | COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS | May 2023 | October 2024 | Abandon | 18 | 1 | 0 | Yes | No |
| 18309047 | METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTURE | April 2023 | December 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18140326 | TAIL-CONJUGATED RNAS | April 2023 | May 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18029158 | COMPOSITIONS AND METHODS FOR CD30 GENE MODIFICATION | March 2023 | March 2026 | Abandon | 36 | 0 | 1 | No | No |
| 18114317 | CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPY | February 2023 | August 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18110528 | T CELLS EXPRESSING CHEMOKINE RECEPTORS FOR TREATING CANCER | February 2023 | January 2026 | Abandon | 35 | 3 | 1 | Yes | No |
| 18108869 | METHODS AND SYSTEMS FOR T CELL EXPANSION | February 2023 | July 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 18167598 | Compositions and Methods of Treating Ocular Diseases | February 2023 | January 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18157494 | METHODS OF GENERATING POPULATIONS OF TUMOUR-INFILTRATING T CELLS | January 2023 | March 2026 | Abandon | 38 | 2 | 1 | No | No |
| 18157598 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | January 2023 | November 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 18016972 | DUAL CAR-T CELLS | January 2023 | January 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18152464 | METHOD FOR ENHANCING PROLIFERATION CAPABILITY OF STEM CELLS USING ETHIONAMIDE | January 2023 | November 2024 | Allow | 23 | 3 | 1 | Yes | No |
| 18004638 | IMMUNE CELLS WITH INCREASED GLYCOLYTIC FLUX | January 2023 | February 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18149396 | METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING NIP7 AND A PHARMACEUTICAL COMPOSITION COMPRISING A NIP7 INHIBITOR | January 2023 | September 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 18149151 | Intrathecal Delivery of Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 | January 2023 | March 2025 | Allow | 26 | 3 | 1 | Yes | No |
| 18068319 | CELLS EXPRESSING RECOMBINANT GROWTH FACTOR RECEPTORS | December 2022 | June 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18063589 | NOVEL ADENO-ASSOCIATED VIRUS CAPSID PROTEINS | December 2022 | October 2024 | Abandon | 22 | 2 | 0 | No | No |
| 17927663 | DIFFERENTIAL KNOCKOUT OF A HETEROZYGOUS ALLELE OF SAMD9L | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18057960 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE | November 2022 | February 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 17992168 | DEVICES AND METHODS FOR SIMULATING A FUNCTION OF LIVER TISSUE | November 2022 | September 2025 | Abandon | 33 | 4 | 1 | No | No |
| 18054500 | Gene Therapy For Neurodegenerative Disorders | November 2022 | January 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 17982753 | NUCLEOSIDE MODIFIED MRNA AND USES THEREOF | November 2022 | March 2025 | Allow | 28 | 2 | 2 | Yes | No |
| 18046363 | Gene Therapy For Neurodegenerative Disorders | October 2022 | March 2024 | Allow | 17 | 2 | 0 | Yes | Yes |
| 17958904 | T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | October 2022 | June 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17882127 | CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | August 2022 | January 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17882036 | CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | August 2022 | January 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17882182 | CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | August 2022 | April 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17814287 | DIMERIZATION SWITCHES AND USES THEREOF | July 2022 | August 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17794939 | COMPOUNDS AND METHODS FOR TREATING OR REDUCING PRURITUS | July 2022 | October 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17793626 | PREVENTION OF PLATELET ACTIVATION AND CELL DIFFERENTIATION DURING THE PROCESSING OF BLOOD AND BLOOD-RELATED COMPOSITIONS | July 2022 | October 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17866022 | VIRAL VECTORS FOR TREATING NEUROGENIC DETRUSOR OVERACTIVITY | July 2022 | October 2025 | Allow | 39 | 6 | 1 | Yes | Yes |
| 17789739 | INTRAPANCREATIC M2 POLARIZATION OF MACROPHAGES TO TREAT TYPE 1 DIABETES | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17851430 | CONUS-BASED TOXIN PEPTIDES, NUCLEIC ACIDS ENCODING SAME AND USES THEREOF IN MODULATING NMDA RECEPTORS | June 2022 | January 2026 | Allow | 43 | 1 | 1 | Yes | No |
| 17747618 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | May 2022 | June 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17663344 | LMP-1 EXPRESSING CELLS AND METHODS OF USE THEREOF | May 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17741744 | ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS | May 2022 | February 2023 | Abandon | 9 | 0 | 0 | No | No |
| 17742209 | TARGETING GLIOBLASTOMA STEM CELLS THROUGH THE TLX-TET3 AXIS | May 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17774732 | COMBINED THERAPY FOR MUSCULAR DISEASES | May 2022 | February 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17766648 | T CELLS MODIFIED TO EXPRESS MUTATED CXCR4 OR PARTIALLY DELETED AND USES THEREOF | April 2022 | December 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17766369 | COMPOSITION FOR REPROGRAMMING CELLS INTO PLASMACYTOID DENDRITIC CELLS OR INTERFERON TYPE I-PRODUCING CELLS, METHODS AND USES THEREOF | April 2022 | December 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17765872 | METHODS OF ENGINEERING PLATELETS FOR TARGETING CIRCULATING TUMOR CELLS | April 2022 | January 2026 | Allow | 45 | 0 | 1 | Yes | No |
| 17709208 | VISMODEGIB IN COMBINATION WITH A REPLICATION-DEFICIENT TYPE 5 ADENOVIRUS FOR EXPRESSION OF INTERFERON GAMMA FOR THE TREATMENT OF SKIN CANCER | March 2022 | March 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17762529 | COMPOSITIONS AND METHODS TO TREAT METASTATIC GASTROINTESTINAL CANCER | March 2022 | December 2025 | Allow | 44 | 0 | 1 | Yes | No |
| 17642985 | NEW ONCOLYTIC NEWCASTLE DISEASE VIRUSES AND RECOMBINANT NDV STRAINS | March 2022 | December 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17760724 | METHODS AND COMPOSITIONS FOR TREATING MYC-DRIVEN CANCERS | March 2022 | July 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17681167 | UNIVERSAL CAR-T CELL AND PREPARATION METHOD AND USE THEREOF | February 2022 | March 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17665084 | ISOLATION OF FUSION-COMPETENT MYOBLASTS AND THERAPEUTIC APPLICATIONS THEREOF RELATED TO MUSCULAR DYSTROPHY | February 2022 | July 2025 | Abandon | 41 | 2 | 0 | No | Yes |
| 17632686 | GENETICALLY ENGINEERED ONCOLYTIC VACCINIA VIRUSES AND METHODS OF USES THEREOF | February 2022 | September 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17590557 | RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS TO TARGET MEDULLARY THYROID CARCINOMA | February 2022 | December 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17629627 | Aptamer-Based Multispecific Therapeutic Agents | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17626360 | P21 Expressing Monocytes for Cancer Cell Therapy | January 2022 | September 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17625483 | ONCOLYTIC NON-HUMAN ADENOVIRUSES AND USES THEREOF | January 2022 | February 2026 | Allow | 50 | 1 | 1 | Yes | No |
| 17623978 | Use of LRP2 Agonists for Generating Myeloid-Derived Suppressor Cells | December 2021 | July 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17622224 | NUCLEIC ACID AGENTS MODULATING SLAMF6 ISOFORMS | December 2021 | November 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17620775 | METHODS FOR TRANSFORMATION OF FUNGAL SPORES | December 2021 | November 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17617336 | METHODS AND COMPOSITIONS FOR REDUCING GENE OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSES | December 2021 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17540289 | METHOD FOR PREVENTING OR TREATING METABOLIC DISORDER | December 2021 | July 2023 | Allow | 19 | 0 | 1 | Yes | No |
| 17610840 | INDUCING IMMUNE TOLERANCE BY rAAV VECTORS | November 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17523627 | COMPOSITIONS AND METHODS FOR SELECTIVE GENE REGULATION | November 2021 | June 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17516149 | TUMOR CELL VACCINES | November 2021 | February 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17606890 | OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USE | October 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17604556 | GENE THERAPIES FOR STARGARDT DISEASE (ABCA4) | October 2021 | July 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17503132 | COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIES | October 2021 | March 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17602530 | NUCLEIC ACID MAZZOCCHIO AND METHODS OF MAKING AND USE THEREOF | October 2021 | October 2025 | Allow | 49 | 0 | 1 | Yes | No |
| 17447231 | VECTORIZED ANTIBODIES AND USES THEREOF | September 2021 | April 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17377972 | HIGH CONCENTRATION FORMULATIONS | July 2021 | October 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17357704 | CYTOTOXIC MOLECULES RESPONSIVE TO INTRACELLULAR LIGANDS FOR SELECTIVE T CELL MEDIATED KILLING | June 2021 | October 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17342013 | SYNP162, A PROMOTER FOR THE EXPRESSION OF GENES | June 2021 | November 2022 | Allow | 17 | 0 | 0 | Yes | No |
| 17327719 | CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPY | May 2021 | August 2023 | Abandon | 27 | 4 | 1 | No | No |
| 17325417 | Methods and Gene Therapy Constructs for Treating GM2 Gangliosidoses | May 2021 | December 2022 | Allow | 19 | 0 | 0 | Yes | No |
| 17288075 | PHARMACEUTICAL COMPOSITION COMPRISING ISOLATED MITOCHONDRIA FOR PREVENTING OR TREATING TENDINOPATHY | April 2021 | June 2025 | Allow | 50 | 2 | 0 | No | No |
| 17223875 | SYNP159, A PROMOTER FOR THE EXPRESSION OF GENES | April 2021 | October 2022 | Allow | 19 | 0 | 0 | Yes | No |
| 17222812 | GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF | April 2021 | September 2022 | Allow | 17 | 2 | 1 | Yes | No |
| 17209035 | Method for Producing Culture Containing Megakaryocytes, and Method for Producing Platelets Using Same | March 2021 | January 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17274062 | CHIMERIC ANTIGEN RECEPTOR FOR SOLID CANCER AND T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | March 2021 | January 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17186039 | CELL-DERIVED PARTICLES PRESENTING HETEROLOGOUS CD24 AND USE THEREOF IN THERAPY | February 2021 | December 2023 | Abandon | 34 | 4 | 1 | Yes | Yes |
| 17183593 | METHODS OF MODULATING M2 MACROPHAGE POLARIZATION AND USE OF SAME IN THERAPY | February 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17268328 | CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3 | February 2021 | November 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17141142 | BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS | January 2021 | May 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17256141 | Composition and Methods for Producing Insulin Producing Islet Cells | December 2020 | January 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17133187 | MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES HAVING INCREASED CYTOTOXICITY | December 2020 | October 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 17107461 | ADENO-ASSOCIATED VIRUS VARIANTS AND METHODS OF USE THEREOF | November 2020 | November 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16952801 | RECOMBINANT GLUT1 ADENO-ASSOCIATED VIRAL VECTOR CONSTRUCTS AND RELATED METHODS FOR RESTORING GLUT1 EXPRESSION | November 2020 | December 2025 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 17055525 | MANIPULATING ARID5B EXPRESSION IN IMMUNE CELLS TO PROMOTE METABOLISM, SURVIVAL, AND FUNCTION | November 2020 | June 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17096502 | MODULATION OF LIVER GENES | November 2020 | August 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17052818 | METHOD FOR TREATING AND MODELLING HEARING LOSS | November 2020 | August 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 17084963 | NOVEL THERAPEUTICAL TOOLS AND METHODS FOR TREATING BLINDNESS BY TARGETING PHOTORECEPTORS | October 2020 | November 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16771781 | METHOD FOR PRODUCING ACTIVE GCMAF | October 2020 | March 2025 | Allow | 57 | 3 | 0 | Yes | No |
| 17050694 | ANTI-BCMA CAR-T-CELLS FOR PLASMA CELL DEPLETION | October 2020 | January 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17047761 | Cell-Containing Hydrogel Body and Method for Producing Same | October 2020 | March 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17047515 | Modification of Immune Cells to Increase Activity | October 2020 | July 2024 | Abandon | 45 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GRABER, JAMES J.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GRABER, JAMES J works in Art Unit 1631 and has examined 112 patent applications in our dataset. With an allowance rate of 44.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 52 months.
Examiner GRABER, JAMES J's allowance rate of 44.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GRABER, JAMES J receive 2.63 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GRABER, JAMES J is 52 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +57.4% benefit to allowance rate for applications examined by GRABER, JAMES J. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.5% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 84.4% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.